Ann: Investor Update, page-109

A key business issue over the last couple of quarters was that Abiomed, our foundation customer. had a significant drop in order volume. In the investor update we were informed this has been resolved.

Abiomed is a cornerstone customer and Sensera has workedwith the company for over six years supplying: Sensors (consumables) – an optical sensor to guide the Impella®catheter placement. Optical Benches (base unit) – a controller to manage the heartvalve flow and performance.

Sensera was consistently increasing sensor shipments to Abiomed, however, Abiomed has suffered technical issues in
recent quarters and this has disrupted order consistency.

Abiomed has now overcome these issues and sensor purchase volumes have improved in the current quarter and are expected
to return to growth in FY22.

Sensera will supply four products (previously one). Three areconsumable items (sensors) and therefore demand will bedriven by Abiomed volumes. The other product is the bench.

The Q4 sales forecast for Abiomed is $0.5M, next quarter $0.78M.
Given this statement on operating costs, getting Abiomed up to $1M sales per quarter is business critical

Sensera has successfully reduced costs to lower the threshold forprofitability – go-forward quarterly overhead is ~US$1.0m (post fabcost absorption) a 30% reduction over the previous year.

As such, the following release from Abiomed on Q1 results ( Jan - Mar 21) was very encouraging and tells us Impella sales are back on track, and re-enforces the position taken by Sensera in the investor update :

• U.S.Impella product revenue for the quarter totaled$186.1 million, an increase of 13% compared to revenue of$164.0 millionduring the same period of the prior fiscal year withU.S.patient usage of the Impella heart pumps up 13%. Full yearU.S.

• Outside theU.S., Impella product revenue for the quarter totaled$44.3 million, an increase of 33% compared to revenue of$33.4 millionduring the same period of the prior fiscal year. Full year Impella product revenue outside theU.S.totaled$151.1 million, an increase of 14% compared to$132.4 millionin the prior fiscal year.Japanrevenue was$11.6 millionfor the quarter and$42.9 millionfor the year, up 38% and 22%, respectively, compared to prior fiscal year.

IMO. GLTAH